Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q2 2026
Cumberland Pharmaceuticals (CPIX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
Cumberland Pharmaceuticals (CPIX) reported revenue of $8.8M for the second quarter 2026 (Q2 2026), -19% from a year earlier and -4% from the quarter before. Operating margin was -35.9%, net loss $4.3M (48.6% of revenue).
Cumberland Pharmaceuticals, Q2 2026: revenue $8.8M (-19% year over year), operating margin -35.9%, net loss $4.3M, operating cash flow $169K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.8M | -4% | -19% |
| Operating profit | −$3.2M | — | — |
| Net earnings | −$4.3M | — | — |
| Operating cash flow | $169K | -56% | -80% |
| Free cash flow | $130K | -66% | -84% |
What changed
Revenue was $8.8M in Q2 2026, down 19% year over year and down 4% from the previous quarter. Talicia was the largest line at 27% of revenue. Kristalose lost $1.7M year over year (down 61%), 83% of the total change.
Operating costs exceeded revenue by $3.2M, an operating margin of -35.9%. Total costs fell 14% while revenue fell 19%. The fastest-growing cost line was Other operating costs (+104%). The quarter ended with a net loss of $4.3M, wider than the previous quarter's $3.3M loss.
Operating cash flow was $169K (down 80% year over year). Non-cash charges added back $78K of share-based compensation. Working capital and other items added $4.4M. Capital expenditures of $38K left free cash flow of $130K.
Questions
What was Cumberland Pharmaceuticals' revenue in the second quarter 2026?
Cumberland Pharmaceuticals (CPIX) reported revenue of $8.8M for the second quarter 2026 (Q2 2026), -19% from a year earlier and -4% from the quarter before.
Was Cumberland Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $3.2M (-35.9% of revenue) and net loss $4.3M.